Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 6/20 | 0.63 |
| ▸ | NAMPT | P43490 | 4/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CDK8 | P49336 | 3/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103497 | 0.92 | NAMPT (0.63) | RAF1NAMPTCA1CA2CA7 | |
| SCHEMBL104548 | 0.89 | CA7 (0.63) | RAF1NAMPTCA1CA2CA7 | |
| SCHEMBL171340 | 0.89 | NAMPT (0.60) | RAF1NAMPTCA1CA2CA7 | |
| SCHEMBL16628062 | 0.89 | RAF1 (0.76) | RAF1CA7CA9CDK8KDR | |
| SCHEMBL1790568 | 0.85 | NAMPT (0.65) | NAMPTCA1CA2CA7CA9 | |
| SCHEMBL13648230 | 0.85 | RAF1 (0.66) | RAF1CA7CA9CDK8KDR | |
| SCHEMBL1790385 | 0.85 | CA7 (0.61) | RAF1NAMPTCA1CA2CA7 | |
| SCHEMBL5636169 | 0.85 | RAF1 (0.65) | RAF1CA7CA9CDK8KDR | |
| SCHEMBL6031038 | 0.85 | RAF1 (0.67) | RAF1CA7CA9CDK8KDR | |
| SCHEMBL101750 | 0.84 | RET (0.57) | RAF1NAMPTCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20060199844-A1 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2006-09-07 | — | — | US | disclosed |
| EP-1562905-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004037789-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | RAF1 2/4885NAMPT 1163/4885CA1 3992/4885 |
| US-20060199844-A1 | Methylene urea derivatives | BRAF, RAF1, CMPK1 | RAF1 2/4885NAMPT 1163/4885CA1 3992/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | RAF1 2/4885NAMPT 1163/4885CA1 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.